Correlation Between LMF Acquisition and ZyVersa Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both LMF Acquisition and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining LMF Acquisition and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between LMF Acquisition Opportunities and ZyVersa Therapeutics, you can compare the effects of market volatilities on LMF Acquisition and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in LMF Acquisition with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of LMF Acquisition and ZyVersa Therapeutics.

Diversification Opportunities for LMF Acquisition and ZyVersa Therapeutics

0.91
  Correlation Coefficient

Almost no diversification

The 3 months correlation between LMF and ZyVersa is 0.91. Overlapping area represents the amount of risk that can be diversified away by holding LMF Acquisition Opportunities and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and LMF Acquisition is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on LMF Acquisition Opportunities are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of LMF Acquisition i.e., LMF Acquisition and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between LMF Acquisition and ZyVersa Therapeutics

Considering the 90-day investment horizon LMF Acquisition Opportunities is expected to generate 1.09 times more return on investment than ZyVersa Therapeutics. However, LMF Acquisition is 1.09 times more volatile than ZyVersa Therapeutics. It trades about -0.03 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.09 per unit of risk. If you would invest  11,425  in LMF Acquisition Opportunities on August 31, 2024 and sell it today you would lose (11,175) from holding LMF Acquisition Opportunities or give up 97.81% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy99.79%
ValuesDaily Returns

LMF Acquisition Opportunities  vs.  ZyVersa Therapeutics

 Performance 
       Timeline  
LMF Acquisition Oppo 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days LMF Acquisition Opportunities has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

LMF Acquisition and ZyVersa Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with LMF Acquisition and ZyVersa Therapeutics

The main advantage of trading using opposite LMF Acquisition and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if LMF Acquisition position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.
The idea behind LMF Acquisition Opportunities and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance